• 1. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

Professional Introduction to 2H-PYRAN, 4-BROMOTETRAHYDRO-2,6-DIMETHYL- (CAS No. 78726-17-7)

The compound 2H-PYRAN, 4-BROMOTETRAHYDRO-2,6-DIMETHYL- (CAS No. 78726-17-7) represents a significant advancement in the field of heterocyclic chemistry, particularly within the realm of pharmaceutical intermediates. This compound, characterized by its brominated tetrahydropyran structure, has garnered considerable attention due to its versatile applications in medicinal chemistry and synthetic organic transformations. The presence of both methyl substituents and a bromine atom at the 4-position provides a unique scaffold that is highly conducive to further functionalization, making it a valuable building block for the development of novel therapeutic agents.

In recent years, the exploration of tetrahydropyran derivatives has expanded dramatically, driven by their potential as pharmacophores in drug discovery. The bromine atom at the 4-position serves as an excellent handle for palladium-catalyzed cross-coupling reactions, such as Suzuki-Miyaura and Buchwald-Hartwig couplings, which are pivotal in constructing complex molecular architectures. This reactivity has been leveraged in the synthesis of small-molecule inhibitors targeting various biological pathways. For instance, recent studies have demonstrated the utility of this compound in generating derivatives with anti-inflammatory and antiviral properties.

The dimethyl substituents at the 2- and 6-positions introduce steric and electronic effects that can modulate the binding affinity and selectivity of resulting molecules. This fine-tuning capability is particularly crucial in rational drug design, where subtle changes in molecular structure can lead to significant improvements in pharmacological activity. Researchers have employed computational methods to predict how these substituents influence the conformational flexibility and electronic properties of the pyran ring, providing insights into how best to optimize lead compounds.

One notable application of 2H-PYRAN, 4-BROMOTETRAHYDRO-2,6-DIMETHYL- has been in the synthesis of kinase inhibitors. Kinases are enzymes that play a central role in cell signaling networks, and their dysregulation is implicated in numerous diseases, including cancer. By incorporating this brominated tetrahydropyran core into kinase inhibitors, chemists have been able to develop molecules with enhanced potency and reduced toxicity compared to earlier-generation drugs. The bromine atom allows for further derivatization via transition-metal-catalyzed reactions, enabling the construction of libraries of compounds for high-throughput screening.

Another emerging area where this compound has shown promise is in the development of antimicrobial agents. The rise of antibiotic-resistant pathogens has necessitated the discovery of novel chemical scaffolds with antibacterial activity. The structural features of 4-BROMOTETRAHYDRO-2,6-DIMETHYL-2H-PYRAN make it an attractive precursor for generating molecules that disrupt bacterial cell wall synthesis or interfere with essential metabolic pathways. Preliminary studies have indicated that certain derivatives exhibit promising activity against Gram-positive bacteria, suggesting potential for further development into new therapeutic strategies.

The synthetic methodologies for preparing 78726-17-7 have also seen significant innovation. Modern approaches often involve catalytic hydrogenation or metal-mediated cyclization reactions that afford high yields and excellent regioselectivity. These advances have not only streamlined the production process but also enabled access to previously inaccessible derivatives. The ability to efficiently modify this core structure has spurred interest from both academic researchers and pharmaceutical companies looking to expand their chemical toolkits.

From a computational chemistry perspective, the study of 2H-PYRAN derivatives has provided valuable insights into molecular interactions at an atomic level. Advanced spectroscopic techniques combined with density functional theory (DFT) calculations have allowed researchers to elucidate how different substituents affect electronic distributions and hydrogen bonding networks within these molecules. Such knowledge is critical for designing drugs that not only bind effectively but also exhibit favorable pharmacokinetic properties.

The future prospects for this compound remain highly promising as new synthetic routes are explored and its applications broadened. Collaborative efforts between chemists specializing in heterocyclic chemistry and biologists investigating disease mechanisms are likely to yield groundbreaking discoveries in the coming years. As our understanding of structure-activity relationships continues to evolve, so too will the importance of intermediates like 4-BROMOTETRAHYDRO-2,6-DIMETHYL-2H-PYRAN (CAS No. 78726-17-7) in shaping next-generation therapeutics.

• 62938-19-6(2H-Pyran, 2-(6-bromohexyl)tetrahydro-)
• 34729-09-4(2-(11-Bromoundecyl)oxane)
• 111396-31-7(2,6-Dipropyl-4-bromotetrahydropyran)
• 105509-16-8(2H-Pyran, 4-bromotetrahydro-2,6-bis(1-methylethyl)-)
• 64577-22-6(Cyclooctane, 1-bromo-4-methoxy-, cis-)
• 88404-80-2(2H-Pyran, 4-bromo-2,6-diethyltetrahydro-)
• 68655-87-8(2-(3-bromopropyl)oxane)
• 77564-82-0(3-(2-Bromo-ethyl)-tetrahydro-pyran)
• 20599-95-5(3-Bromo-8-methoxydecane)
• 80778-34-3( )